Phase II study of eribulin mesylate in patients (pts) with advanced soft tissue sarcoma (STS).

被引：2
|
作者：
Naito, Yoichi
Kawai, Akira
Araki, Nobuhito
Ozaki, Toshifumi
Sugiura, Hideshi
Yazawa, Yasuo
Morioka, Hideo
Matsumine, Akihiko
Hiraiwa, Masahide
Asami, Shun
Isu, Kazuo
机构：
[1] Natl Canc Ctr Hosp East, Chiba, Japan
[2] Natl Canc Ctr, Tokyo, Japan
[3] Osaka Med Ctr Canc & Cardiovasc Dis, Osaka, Japan
[4] Okayama Univ Hosp, Okayama, Japan
[5] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[6] Saitama Med Univ, Int Med Ctr, Saitama, Japan
[7] Keio Univ, Tokyo, Japan
[8] Mie Univ, Grad Sch Med, Tsu, Mie, Japan
[9] Eisai, Tokyo, Japan
[10] Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.10567
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10567
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study
    Liu, Jie
    Deng, Yaotiao
    Wang, Ying
    Zhang, Jie
    Li, Mei
    Jiang, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
    Noujaim, Jonathan
    Alam, Salma
    Thway, Khin
    Jones, Robin Lewis
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2016, 37 (03) : 125 - 130
  • [23] Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS)
    Revathi Suppiah
    Laura Wood
    Paul Elson
    George T. Budd
    Investigational New Drugs, 2006, 24 : 509 - 514
  • [24] Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS)
    Suppiah, Revathi
    Wood, Laura
    Elson, Paul
    Budd, George T.
    INVESTIGATIONAL NEW DRUGS, 2006, 24 (06) : 509 - 514
  • [25] Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).
    Suppiah, R
    Budd, GT
    Wood, L
    Elson, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 831S - 831S
  • [26] Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group
    Woll, PJ
    Judson, I
    Lee, SM
    Rodenhuis, S
    Nielsen, OS
    Buesa, JM
    Lorigan, PC
    Leyvraz, S
    Hermans, C
    van Glabbeke, M
    Verweij, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (03) : 410 - 412
  • [27] Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma
    Emambux, Sheik
    Italiano, Antoine
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (08) : 819 - 824
  • [28] Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS)
    Rosenbaum, Evan
    Qin, Li-Xuan
    Dickson, Mark Andrew
    Keohan, Mary Louise
    Gounder, Mrinal M.
    Chi, Ping
    Movva, Sujana
    Kelly, Ciara Marie
    Avutu, Viswatej
    Chan, Jason Earl
    Martindale, Moriah
    Adamson, Travis
    Clark, Camron
    Desir, Rhoena
    Biniakewitz, Matthew
    Cho, Grace
    Erinjeri, Joseph Patrick
    Lefkowitz, Robert A.
    Tap, William D.
    D'Angelo, Sandra P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Assessment of cardiotoxicity (CT) associated with doxorubicin (dox) in patients (pts) with advanced soft tissue sarcoma (STS) in a phase III randomized trial
    Jones, R. L.
    Wagner, A.
    Kawai, A.
    Shahir, A.
    Soldatenkova, V.
    Wright, J.
    Tap, W. D.
    ANNALS OF ONCOLOGY, 2019, 30 : 685 - +
  • [30] Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma
    Bailey, Howard H.
    Mahoney, Michelle R.
    Ettinger, David S.
    Maples, William J.
    Fracasso, Paula M.
    Traynor, Anne M.
    Erlichman, Charles
    Okuno, Scott H.
    CANCER, 2006, 107 (10) : 2462 - 2467
12345